Ardelyx, Inc.

ARDX Healthcare Biotechnology

Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024. In the quarter to June 2026, revenue grew 23.8%, EPS grew 12.5%, free cash flow grew 75.3% and total debt rose 25.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

3.09 0.18 −5.50%
Market cap
$814.9M
P/E
0.0×
Fwd P/E
−122×
Dividend yield
—
F-score
2/9
Altman Z
1.12
Beneish M
−2.40
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
264.69 250.10 184.30 123.91 116.69 186.48 247.51 168.09 133.98 200.82
Receivables
71.85 57.71 22.03 7.73 0.50 — 0.75 5.09 10.80 —
Inventory
17.74 21.17 12.45 3.28 — — — — — —
Total current assets
382.32 356.45 246.11 153.60 133.65 194.69 252.06 176.37 149.71 203.99
Property, Plant, Equpment (Net)
2.18 1.50 1.01 1.22 2.36 1.94 3.44 5.61 8.03 8.99
Long-Term Investments
— — — — — 2.11 — — — —
Long-term assets (Other)
6.94 5.42 7.83 0.88 1.15 0.55 0.31 1.35 0.16 0.15
Total non-current assets
119.29 79.30 51.47 36.46 16.26 6.88 7.72 6.96 8.19 9.14
Total Assets
501.60 435.75 297.58 190.07 149.91 201.56 259.78 183.33 157.90 213.13
Accounts Payable
19.24 16.00 11.14 10.86 4.28 5.63 2.19 1.15 3.93 5.64
Accrued Expenses
19.11 14.94 12.60 7.55 5.42 5.67 4.45 2.72 3.23 3.16
Current Part of Debt
— — — 26.71 32.26 4.17 1.18 — — —
Current Revenue (Deferred)
1.21 10.69 7.18 4.21 — 4.18 4.54 — — —
Other current liabilities
47.58 34.64 15.04 12.38 7.37 6.66 7.25 12.86 10.71 10.41
Total current liabilities
88.61 77.83 50.39 65.60 52.82 28.42 22.22 17.73 17.87 19.20
Long Term Debt (Total)
202.83 150.85 49.82 17.11 9.75 46.62 48.83 49.21 — —
Non-current Revenue (Deferred)
13.70 7.23 8.64 9.03 4.73 — — — — —
Non-current Liabilities (Other)
25.88 25.53 20.18 11.25 — 0.00 0.00 0.58 0.72 0.78
Total non-current liabilities
246.05 184.64 80.37 26.13 14.48 47.03 50.91 49.79 0.72 0.78
Total liabilities
334.66 262.47 130.76 91.74 67.30 75.45 73.13 67.52 18.59 19.98
Additional Paid In Capital
1,113.67 1,058.55 1,012.77 878.50 795.54 680.87 647.08 481.36 417.57 407.09
Common Stock (Net)
0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01
Retained Earnings
(946.94) (885.34) (846.20) (780.14) (712.93) (554.76) (460.45) (365.51) (278.21) (213.87)
Common Equity (Total)
166.95 173.29 166.82 98.33 82.62 126.11 186.66 115.81 139.31 193.15
Shareholders Equity (Total)
166.95 173.29 166.82 98.33 82.62 126.11 186.66 115.81 139.31 193.15
Shareholders Equity and Liabilities (Total)
501.60 435.75 297.58 190.07 149.91 201.56 259.78 183.33 157.90 213.13
Shares (Common)
244.35 238.02 232.45 198.58 130.18 93.60 88.82 62.52 47.54 47.31
Shareholders Equity (Tangible)
166.95 173.29 166.82 98.33 82.62 126.11 186.66 115.81 139.31 193.15
Net Debt
(61.85) (99.25) (134.48) (80.09) (74.68) (135.70) (197.50) (118.88) (133.98) (200.82)
Total Debt
202.83 150.85 49.82 43.82 42.01 50.79 50.01 49.21 — —

Fold the line items

In millions of $ except per-share values · columns are period end dates